PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call

20:00 EDT 14 Mar 2018 | Globe Newswire

HOUSTON, March 15, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced that the Company will release its 2017 fourth quarter and full year financial results on Friday, March 23, 2018, before the U.S. financial markets open.

Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date   Friday, March 23, 2018
Time   8:30 a.m. EDT
Toll free (U.S.)   (866) 394-2901
International   (616) 548-5567
Webcast (live and replay) under the ‘Investor Relations’ section.

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).  The conference ID for the replay is 8198566. The archived webcast will be available for 30 days via the aforementioned URL.

About Aspertec
Aspertec 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.

About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide effective and safe aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793


More From BioPortfolio on "PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call"

Quick Search